达格列净对2型糖尿病合并心血管疾病患者的临床疗效分析

Clinical Efficacy Analysis of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Combined with Cardiovascular Disease

目的:分析达格列净对2型糖尿病合并心血管疾病患者的临床疗效。方法:选取2020年1-12月徐州医科大学附属宿迁医院收治的2型糖尿病合并心血管疾病患者80例作为研究对象,采用随机数字表法分为观察组和对照组,各40例。对照组采用二甲双胍治疗,观察组在对照组基础上添加达格列净联合治疗,比较两组患者临床指标及血糖变化。结果:治疗后,两组患者空腹血糖(FBG)、糖化血红蛋白(HbA_(1c))、甘油三酯、低密度脂蛋白-胆固醇、收缩压和舒张压水平均降低,高密度脂蛋白-胆固醇(HDL-C)水平升高,观察组优于对照组,差异有统计学意义(P<0.05);观察组FBG、餐后2 h血糖、HbA1c变化值高于对照组,差异有统计学意义(P<0.05)。结论:达格列净对糖尿病合并心血管疾病具有良好的降血糖、降血脂、提高抗氧化应激作用,且具有良好的安全性。

Objective:To analyze the clinical efficacy of dapagliflozin in patients with type 2 diabetes mellitus combined with cardiovascular disease.Methods:80 patients with type 2 diabetes mellitus combined with cardiovascular disease admitted to Suqian Hospital Affiliated to Xuzhou Medical University from January to December 2020 were selected as the study subjects,and were divided into observation group and control group using random number table method,40 cases each.The control group was treated with metformin and the observation group was treated with the addition of dapagliflozin on the basis of the control group.The clinical indexes and blood glucose changes of the patients in the two groups were compared.Results:After treatment,fasting blood glucose(FBG),glycated hemoglobin(HbA_(1c)),triglycerides,LDL-cholesterol,systolic and diastolic blood pressure levels decreased and HDL-C levels increased in both groups,with the observation group outperforming the control group.The difference was statistically significant(P<0.05).The FBG,2 h postprandial glucose and HbA1c values in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).Conclusion:Dapagliflozin has good hypoglycemic,hypolipidemic and antioxidant stress effects on diabetes combined with cardiovascular disease,and has a good safety profile.